

1 **Title**

2 **High daily dose Short COurse PrimaquinE after G6PD testing for the radical**
3 **cure of *Plasmodium vivax* malaria in Indonesia and Papua New Guinea: The**
4 **SCOPE implementation study protocol**

5
6 **Authors**

- 7 Jeanne Rini Poespoprodjo, MD, PhD^{1,2}
8 Moses Laman, MD, PhD³
9 Ayodhia Pitaloka Pasaribu, MD, PhD^{4,5}
10 Inge Sutanto, MD, PhD⁶
11 Erni Nelwan, MD, PhD⁶
12 Liony Fransisca, MD²
13 Enny Kenangalem, MD²
14 Faustina Helena Burdam, MD²
15 Vincent Jimanto, MD⁵
16 Framita Ainur, MD⁵
17 Azkarunia Pasidiaz Hutagalung, MD⁵
18 Sherley Angeline, MD⁷
19 Adela Putri, MD⁷
20 Ari Winasti Satyagraha, Dr.sc.hum⁸
21 Minerva Theodora, MD⁹
22 William Pomat, PhD³
23 Maria Ome-Kaius, MD, PhD³
24 Mary Malai, MD³
25 Cynthia Abegini, BRH³
26 Irene Pukai, BRH³
27 Sharol Ronkentuo, BRH³
28 Yolyne Amdara, BRH³
29 Leo Makita, MPH¹⁰
30 Evelien Rosens, MSc¹¹
31 Paul Daly, MPH¹¹
32 Rachael Farquhar, MPH¹¹

33 Nicholas M. Douglas, FRACP^{12,13,14}

34 Kylie Mannion, Grad Dip,¹²

35 Ella Curry, MD, MPH¹²

36 Annisa Rahmalia, MD, MPH, PhD¹²

37 Vanessa S Sakalidis, PhD¹²

38 Jacklyn Adella, MD¹²

39 Grant Lee, BSc¹²

40 Benedikt Ley, PhD¹²

41 Angela Devine, PhD^{12,16}

42 Patrick Abraham, MPH^{12,16}

43 Julie A. Simpson, PhD^{15,19}

44 Katelyn Brown, M(Biost)^{12,15}

45 Thy Do, PhD¹⁷

46 Heike Huegel, MSc¹⁷

47 Helen Demarest, PhD¹⁷

48 Elodie Lambert, PharmD, MPH¹⁷

49 Tanyaporn Wansom, PhD, MD¹⁷

50 Stephan Duparc, PhD, MD¹⁷

51 Leanne J. Robinson, PhD^{2,11,18}

52 Ric N. Price, FRCP^{12,19,20}

53

54 **Affiliations**

55 ¹ Centre for Child Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada,
56 Yogyakarta, Indonesia Indonesia

57 ² Yayasan Pengembangan Kesehatan dan Masyarakat Papua, Timika, Papua, Indonesia

58 ³ Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea

59 ⁴ Department of Pediatrics, Medical Faculty, Universitas Sumatera Utara, Medan, Indonesia

60 ⁵ Tridarma Healthcare Empowerment Foundation, Medan, Sumatera Utara, Indonesia

61 ⁶ Department of Parasitology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia

62 ⁷ Hanura Puskesmas, Lampung, Indonesia

63 ⁸ National Research and Innovation Agency (BRIN), Jakarta, Indonesia

64 ⁹ Indonesian National Malaria Control Program, Jakarta, Indonesia

65 ¹⁰ National Malaria Control Program, National Department of Health, PNG

66 ¹¹ Burnet Institute, Melbourne, VIC Australia

67 ¹² Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin
68 University, Darwin, NT, Australia

69 ¹³ Department of Infectious Diseases, Christchurch Hospital, Te Whatu Ora Waitaha, Christchurch,
70 New Zealand

71 ¹⁴ Department of Medicine, University of Otago, Christchurch, New Zealand

72 ¹⁵ Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The
73 University of Melbourne, Melbourne, Australia

74 ¹⁶ Centre for Health Policy, Melbourne School of Population and Global Health, The University of
75 Melbourne, Melbourne, Australia

76 ¹⁷ Medicines for Malaria Venture, Geneva, Switzerland

77 ¹⁸ Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC,
78 Australia

79 ¹⁹ Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of
80 Oxford, Oxford, UK

81 ²⁰ Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University,
82 Bangkok, Thailand

83

84 **Corresponding author:**

85 Vanessa Sakalidis, PhD

86 Email: scopestudygroup@gmail.com

87 Address: Global and Tropical Health Division, Menzies School of Health Research, PO Box 41096,
88 Casuarina, Darwin, NT 0811, Australia

89

90 **Word count:** 5275

91 **Keywords**

92 *Plasmodium vivax*, Malaria, Primaquine, G6PD, Haemolysis, Indonesia, Papua New Guinea

93

94

95 Abstract

96 **Introduction:** *Plasmodium vivax* malaria remains an important threat to the public in the Asia Pacific
97 region. Preventing *P. vivax* relapses is crucial for reducing morbidity from malaria and ultimately
98 controlling and eliminating this species. Primaquine is the only widely available drug with antirelapse
99 activity against dormant stages of *P. vivax*. Its widespread use in clinical practice is limited by its
100 potential to cause severe haemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD)
101 deficiency.

102 **Methods and analysis:** The primary aims of this staged, binational, multicentre, before-and-after
103 implementation study are to determine the safety, feasibility, and cost-effectiveness of a revised
104 package of case management interventions for improved *P. vivax* radical cure. The interventions
105 include: i) pre-treatment testing of patients for G6PD deficiency using a semi-quantitative point-of-
106 care device from SDBiosensor (ROK); ii) prescription of high dose primaquine (7mg/kg total dose)
107 either over 7 days for G6PD normal patients ($\geq 70\%$ activity) or 14 days for intermediate patients (30-
108 $< 70\%$ activity), or lower dose weekly primaquine over 8 weeks for deficient patients ($< 30\%$ activity);
109 iii) improved patient education processes; iv) routine community-based review on day 3 (and day 7
110 for Stage 1) and v) enhanced malariometric surveillance and community pharmacovigilance. Stage 1
111 of the study (800 patients) will be implemented at 4 community clinics across Indonesia and Papua
112 New Guinea (PNG) and will focus on analysis of treatment safety. If safety of the intervention is
113 confirmed during Stage 1, the study will proceed to Stage 2, in which patient recruitment will be
114 expanded to 10 clinics across Indonesia and PNG, and the feasibility of the similar intervention
115 package will be assessed, but with a single community-based review on day 3. Stage 2 will run for 12
116 months and recruit approximately 11,410 patients. Mixed methods analyses of Stage 2 data will
117 focus on the operational feasibility and cost-effectiveness of the revised case management package,
118 with effectiveness determined through analysis of individual-level risk of *P. vivax* recurrence and
119 population-level changes in incidence (with comparison to the pre-implementation period).

120 Feasibility will be assessed via qualitative observations, in-depth interviews and focus groups of
121 health care workers and participants.

122 **Discussion:** The intervention package will provide critical information on the safety, feasibility and
123 cost-effectiveness of achieving radical cure with G6PD testing prior to high dose primaquine
124 treatment and community-based follow-up. The study results will inform national malaria programs
125 aiming to eliminate *P. vivax* in Indonesia and PNG by 2030.

126 **Ethics and dissemination:** This study has been approved by the World Health Organization Ethics
127 Committee (Indonesia: ERC 0003810, PNG: ERC 0003892); Menzies School of Health Research (HREC:
128 2023-4524), Alfred Health (Burnet Institute) (Project No: 18/23), University of Gadjah Mada
129 (KE/FK/0079/EC/2023), University of Indonesia (KET-347/UN2.F1/ETIK/PPM.00.02/2023), University
130 of Sumatra Utara (80/KEPK/USU/2023), Institute of Tropical Medicine (1655/23), PNG Institute of
131 Medical Research (PNGIMR) (IRB: 22.02), and the PNG National Department of Health Medical
132 Research Advisory Committee (MRAC: 22.66). The study was registered on clinicaltrials.gov for
133 Indonesia: NCT05879224 and PNG: NCT05874271. All participants will provide written, informed
134 consent to join the study. For qualitative observations of health workers, a waiver of consent was
135 granted by all ethics committees, and health centres will be made aware that observations on staff
136 will be carried out. Dissemination plans include presentations at scientific conferences, peer-
137 reviewed publications, and reporting at the national and community level.

138

139 **Strengths and limitations of this Study**

- 140 • The staged design of this study will enable confirmation of the safety of high daily dose
141 primaquine and provide operational insights on G6PD testing and community-based reviews,
142 thereby facilitating the adoption of optimal practices in preparation for wide scale roll-out.

- 143 • Stage 2 will follow real-world conditions with treatment and follow-up embedded within
144 local clinic procedures and implemented by clinic healthcare staff and community-based
145 health workers. These efforts will enable a realistic assessment of the interventions'
146 feasibility, cost-effectiveness, and scalability.
- 147 • Study sites in Indonesia and PNG are publicly funded facilities servicing populations from
148 areas with markedly different malaria endemicity and workloads, supporting the
149 generalisability of our results to regions across both countries with varying malaria
150 epidemiology.
- 151 • Implementation of the intervention may be limited by the informed consent process,
152 potentially restricting enrolment and coverage of the intervention across the study clinics.
- 153 • Multiple time-varying confounders, such as government-initiated malaria control activities,
154 may influence malaria incidence and, therefore, impair the ability to determine the true
155 population-level impact of the study interventions.

156

157 BACKGROUND

158 *Plasmodium vivax* has become the predominant cause of malaria in the Asia-Pacific region (1). *P.*
159 *vivax* is more difficult to eliminate than *P. falciparum* because it forms dormant liver stages
160 (hypnozoites) that can reactivate weeks to months after the initial infection, resulting in recurrent
161 blood stage infections, known as relapses. In some endemic regions, approximately 80% of *P. vivax*
162 cases are caused by relapses (2). In 2022, a total of 101,300 cases of vivax malaria were reported in
163 Indonesia and 211,000 cases in Papua New Guinea (PNG), with the most significant burden occurring
164 in remote and rural areas (3). The governments of both countries have committed to eliminating *P.*
165 *vivax* by 2030; accomplishing this ambitious goal will require innovative strategies to ensure the
166 widespread availability of well-tolerated and effective radical cure of individuals harbouring blood
167 and/or liver stages of the parasite.

168 The 8-aminoquinoline compounds, primaquine and tafenoquine, are the only licensed antimalarial
169 drugs that kill hypnozoites and thus can prevent subsequent relapses of *P. vivax*. Both drugs can
170 cause severe haemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency (4,
171 5). Tafenoquine was approved by the US and Australian health authorities in 2018 and is given as a
172 single dose, facilitating patient adherence (6-8). Currently, tafenoquine can only be prescribed in
173 combination with chloroquine to patients with >70% G6PD enzymatic activity, making access to this
174 drug limited in the many endemic countries where routine G6PD testing is unavailable (9).
175 Primaquine has been the primary treatment for preventing *P. vivax* relapses for almost 70 years and
176 is used in combination with chloroquine and artemisinin-based combination therapies (ACTs) (5).
177 Primaquine is widely available, but its population-level effectiveness is confounded by suboptimal
178 dosing, poor adherence of patients to prolonged treatment courses (10) and the reluctance of
179 healthcare providers to prescribe the drug due to concerns of severe haemolysis in G6PD-deficient
180 patients (11).

181

182 The World Health Organization (WHO) antimalarial treatment guidelines currently recommend a low-
183 dose primaquine regimen (total dose of 3.5mg/kg administered as 0.25mg/kg/day over 14 days or
184 0.5 mg/kg/day over 7 days) (12). The 14-day regimen is most commonly used in *P. vivax*-endemic
185 countries (13). It is recommended that all patients are tested for G6PD deficiency before
186 administration of primaquine. If an individual is diagnosed with G6PD deficiency (<30% enzyme
187 activity), then an 8-week regimen of 0.75mg/kg primaquine administered once per week is
188 recommended (12). In PNG, the national policy for radical cure is primaquine after pre-treatment
189 testing for G6PD deficiency, combined with blood schizonticidal treatment with artemether-
190 lumefantrine (14). The same radical cure regimen in Indonesia is combined with dihydroartemisinin-
191 piperazine (15). In practice, G6PD testing is rarely available and hence the national malaria control
192 programmes (NMCPs) recommend a low daily dose of primaquine (0.25 mg/kg/day) administered
193 over 14 days to reduce the risk of drug-induced haemolysis (11, 13). Adherence to this prolonged
194 treatment course is typically poor when unsupervised (16, 17). Partial supervision, conversely, has
195 been shown to improve adherence and anti-relapse effectiveness (10, 18, 19).

196

197 The antirelapse efficacy of primaquine is related to the total dose administered, whereas safety and
198 tolerability are related to the daily dose administered (20). A recent meta-analysis of the antirelapse
199 efficacy of primaquine demonstrated that the overall risk of recurrent *P. vivax* within 6 months was
200 51.0% (95% confidence interval (CI) 48.2–53.9%) in patients who were not treated with primaquine,
201 19.3% (95%CI: 15.9-21.9%) in patients treated with low-dose primaquine (~3.5mg/kg total dose), and
202 8.1% (95% CI: 7.0-9.4%) for patients treated with high-dose primaquine (~7mg/kg total dose). The
203 benefits of the higher total dose regimen were apparent in both low and high relapse periodicity
204 areas (21).

205

206 Reducing the duration of primaquine treatment has the potential to improve adherence, but requires
207 the same total dose to be administered over a shorter period, thereby increasing the daily dose
208 needed and the subsequent risk of drug induced haemolysis for patients. Two recent clinical trials
209 conducted in Thailand, Afghanistan, Indonesia, Ethiopia and Vietnam (22, 23) have demonstrated
210 that a short-course high daily dose of primaquine (1mg/kg/day over 7 days – PQ7) is non-inferior to
211 the standard high dose regimen (0.5 mg/kg/day administered over 14 days with supervision – PQ14).
212 However, PQ7 was associated with more adverse events, particularly gastrointestinal intolerance
213 (22, 23). The latter can be mitigated by coadministration with food.

214 G6PD deficiency is an X-linked inherited trait. Whereas males are hemizygous normal or deficient,
215 females can be homozygous normal, homozygous deficient or heterozygous for the G6PD gene (24).
216 The latter is associated with a variable degree of intermediate deficiency and an increased risk of
217 haemolysis (25, 26). A recent systematic review demonstrated that early indicators of significant
218 haemolysis are typically apparent within 5 days of treatment commencement and usually precede
219 severe clinical compromise and the need for medical intervention (27). These findings suggest that
220 routine clinical review within 3-5 days of starting primaquine may facilitate early detection of
221 haemolysis so that treatment can be ceased and severe consequences of primaquine-induced
222 haemolysis avoided (27).

223

224 Over the last decade a series of point-of-care tests for G6PD deficiency have been developed and
225 marketed to screen for patients at risk of primaquine or tafenoquine-induced haemolysis (28-30).
226 The SD Biosensor provides reliable differentiation of patients with deficient (<30%), intermediate
227 (30-<70%) and normal (\geq 70%) G6PD activity within 2 minutes using one drop of capillary blood,
228 therefore lending itself to pre-treatment testing.

229

230 In collaboration with Indonesian and PNG policymakers, the SCOPE study was devised to evaluate a
231 revised and enhanced *P. vivax* case management protocol developed to improve access to well-
232 tolerated and effective radical cure. The study is anticipated to inform Indonesian and PNG treatment
233 guidelines and is relevant to other *P. vivax* endemic countries.

234

235 METHODS AND ANALYSIS

236 Introduction to Study Design and Setting

237 The SCOPE study is a pragmatic, staged, binational, multicentre, before-versus-after implementation
238 study of a revised case management package aimed at optimising radical cure for patients with vivax
239 malaria presenting to community health clinics in Indonesia and PNG (Figure 1). Ten publicly funded
240 clinics (6 in Indonesia and 4 in PNG) servicing areas with widely disparate *P. vivax* incidence have
241 been selected for the study (Figure 2). The annual caseloads range from 412 to 4,937 patients per
242 annum and this spectrum of endemicity will support the generalisability of study results (Table 1).

243 The revised case management protocol incorporates five novel components:

- 244 i. Pre-treatment testing of patients for G6PD deficiency using the semi-quantitative point-of-
245 care SD Biosensor device.
- 246 ii. Prescription of high dose primaquine (7mg/kg total dose) over 7 days (G6PD normal patients
247 - $\geq 70\%$ activity, ≥ 6.1 U/gHb), or over 14 days (intermediate patients - $30\text{--}70\%$ activity, 4.1--
248 6.0 U/gHb) or primaquine one a week for 8 weeks (deficient patients - $<30\%$ activity, ≤ 4.0
249 U/gHb) (Table 2).
- 250 iii. Improved patient education processes, including supervision of the first dose of primaquine
251 and counselling regarding key risks and benefits of therapy as well as the necessity to take
252 doses with food.

- 253 iv. Routine community-based review on day 3 (and day 7 for Stage 1) for the dual purpose of
254 encouraging adherence to primaquine and detecting early warning signs of impending
255 severe haemolysis and other adverse effects
- 256 v. Enhanced malariometric surveillance and community pharmacovigilance to support wider-
257 scale use of the revised case management package

258

259 The study uses a staged approach. Stage 1 aims to build confidence that short course, high dose
260 primaquine can be implemented safely before progressing to Stage 2, in which a large-scale
261 implementation study will be conducted of the revised case management protocol under conditions
262 more closely matching real-world practice. The overarching aim of the study is to determine the
263 safety, operational feasibility and cost-effectiveness of the revised case management protocol. The
264 study will be conducted over 21 months, and the results will be reported in line with the CONSORT
265 extension (31) and SPIRIT statement (32) (Supplementary data 1).

266

267

268 **Figure 1.** Study schedule

269

270 **Figure 2.** Location of study clinics

271

272

273 **Table 1:** Study Clinics estimated *P. vivax* episodes per year.

Clinic name	Country	Locality	Estimated total number of <i>P. vivax</i> episodes per year	Estimated maximum recruitment in SCOPE Stage 2 (95%)
Timika	Indonesia	Timika, Central Papua	3,173	3,014
Bhintuka	Indonesia	Timika, Central Papua	1,164	1,106
Pasar Sentral	Indonesia	Timika, Central Papua	4,937	4,690
Wania	Indonesia	Timika, Central Papua	3,681	3,497
Tanjung Leidong	Indonesia	North Sumatra	500	475
Hanura	Indonesia	Lampung	450	428
Baro	PNG	West Sepik	417	396
Mugil	PNG	Madang	1,044	992
Napapar	PNG	East New Britain	412	391
Wirui	PNG	East Sepik	1,382	1,313
		Total	17,160	16,302

274

275

276

Footnotes: Estimates based on previous clinic records and number of patients with *P. vivax* recruited over last 12 months. Maximum enrolment assumes 5% of patients are ineligible because they are pregnant, lactating or under 6-12 months of age.

Table 2. Summary of *P. vivax* patient eligibility and treatment in the different stages of the study

	Pre Implementation ¹	Stage 1 Safety & Feasibility	Stage 2 Implementation
G6PD Activity >70% (≥ 6.1 U/gHb)	ACT plus low dose PQ14 (0.25 mg/kg/day)	ACT plus high-dose PQ7 (1mg/kg/day)	ACT plus high-dose PQ7 (1mg/kg/day)
G6PD Activity 30-70% (4.1-6.0 U/gHb)		ACT plus high-dose PQ14 (0.5 mg/kg/day)	ACT plus high-dose PQ14 (0.5 mg/kg/day)
G6PD Activity <30% (≤ 4.0 U/gHb)		ACT plus PQ8W (0.75 mg/kg/week)	ACT plus PQ8W (0.75 mg/kg/week)
Pregnant ²	Treatment as per national guidelines	Ineligible for study, treatment as per national guidelines	Ineligible for study, treatment as per national guidelines
Lactating			
<6m or <5kg in Indonesia			
<1 year in PNG			
Hb <8g/dL			
Previous adverse reaction to PQ			
Severe malaria			

G6PD: Glucose-6-phosphate dehydrogenase; Hb: haemoglobin; ACT: Artemisinin-based combination therapies ; PQ: Primaquine.

¹ No G6PD testing – data during this stage will be gathered from ongoing surveillance.

² Confirmed pregnancy or pregnancy status unknown.

196 Study components and data collection

197 *Pre-implementation*

198 The study will commence with a pre-implementation stage during which continuous malariometric
199 surveillance at all 10 clinics will document clinic case numbers, building upon pre-existing
200 surveillance data collection systems. Incidence data collected during the pre-implementation and
201 Stage 1 recruitment periods (Figure 1) will provide a reference for comparing post-implementation
202 incidence. Midway through the pre-implementation stage, 200 consecutive patients with fever
203 presenting to each clinic will be recruited into a cross-sectional survey assessing the microscopy-
204 based prevalence of *P. vivax* and G6PD activity (Table 3, Figure 3). The pre-implementation phase
205 will last three months for the four clinics participating in Stage 1 of the study and 9 months for the
206 remaining 6 clinics.

207

208 **Table 3.** Study Procedure and Data Collection in Pre-implementation Stage

Research Activity	Day of Collection	Study Procedures	Data Collection
Surveillance	Day 0	<ul style="list-style-type: none">• Routine care only	<ul style="list-style-type: none">• Routine clinic data
Pre-implementation Survey	Day 0	<ul style="list-style-type: none">• Written informed consent• Capillary blood sample for malaria diagnosis, G6PD and Hb	<ul style="list-style-type: none">• Malaria diagnosis, Hb and G6PD activity
Community Pharmacovigilance	Continuous	<ul style="list-style-type: none">• Passive detection of serious adverse events in patients presenting to clinic and hospital	<ul style="list-style-type: none">• Records of all serious adverse events (Supplementary Material 4)
Qualitative Interviews and Focus Groups	Continuous	<ul style="list-style-type: none">• Field testing In-depth interviews and focus group tools with key stakeholders• Observations of routine health care activities	<ul style="list-style-type: none">• Transcripts and summaries of interviews• Observations notes and memos
Health Economic Survey	Day 0 and Day 7	<ul style="list-style-type: none">• Household cost survey per <i>P. vivax</i> episode at each clinic	<ul style="list-style-type: none">• Direct and indirect costs to patients and any caregivers

209 G6PD: Glucose-6-phosphate dehydrogenase; Hb: haemoglobin.

210

211 *Stage 1*

212 Following three months of pre-implementation, Stage 1 of the SCOPE study will commence at two
213 clinics in Papua, Indonesia and two in PNG, with a planned recruitment duration of 6-12 months.
214 This study component aims to provide preliminary safety and feasibility data before progressing to
215 Stage 2 at all ten clinics. A total of 800 patients with non-severe *P. vivax* mono- or mixed species
216 infection diagnosed by microscopy or rapid diagnostic test will be enrolled (500 in Indonesia and 300
217 in PNG) and, following pre-treatment G6PD activity assessment using the SD Biosensor, patients will
218 receive primaquine according to the dosing schedules outlined above (Table 2 and Supplementary
219 Data 2). Community-based follow-up assessments by study nurses will be conducted on day 3 and
220 day 7 of treatment (Supplementary Data 3; Level 2 Review Form), with G6PD activity and
221 haemoglobin assessed on both days. Patients with severe adverse events (SAE) or adverse events of
222 special interest (AESI) will be referred to the clinic for a health practitioner-led clinical review
223 (Supplementary Data 3; Level 3 Review Form and SAE form) and referred to the hospital for medical
224 management if appropriate. All patients will also receive enhanced education and counselling as per
225 the study interventions specified previously (Table 4).

226 **Figure 3.** Schedule of enrolment, interventions, and assessments.

227

228 ¹Day 3 review may be a phone call if the CHW cannot access the patient at home, or at the clinic if
229 the patient presents there. ²During Stage 2 200 consecutive febrile patients at each clinic will be
230 consented for the post-implementation survey, which includes the following procedures: Hb, G6PD
231 and Microscopy only. If positive for vivax malaria, patients will also be recruited to Stage 2.

232 ³Microscopy will only be performed for 200 consecutive febrile patients at each clinic during post-
233 implementation survey, not Stage 2.

234 ⁴Any AESI/SAE identified during study participants' primaquine treatment will be captured.

235

236

237

238

239

240

241

242

243

244

245 **Table 4** Study Procedure and Data Collection in Stage 1

Research Activity	Day of Collection	Study Procedures	Data Collection
Enrolment and Baseline	Day 0	<ul style="list-style-type: none"> • Clinical review • Capillary blood sample for malaria diagnosis by microscopy or rapid diagnostic test (clinic procedure) • Written informed consent • If malaria positive, a 2nd capillary blood sample for G6PD and Hb measurement • Treatment prescribed • Education package • Supervision of first dose • Supply of drugs 	<ul style="list-style-type: none"> • Routine clinic data • Day 0 Hb and G6PD activity, malaria diagnosis, PQ treatment
Level 2 Review	Day 3 and 7	<ul style="list-style-type: none"> • Capillary blood sample for Hb measurement • Signs and symptoms questionnaire by research nurse 	<ul style="list-style-type: none"> • Day 3 signs and symptoms • Day 7 signs and symptoms • Day 3 Hb • Day 7 Hb • SAEs and AESIs
Level 3 Review	When referred from Level 2	<ul style="list-style-type: none"> • Capillary blood sample Hb measurement • Signs and symptoms questionnaire by medical practitioner 	<ul style="list-style-type: none"> • Hb, MetHb • Signs and symptoms • SAEs and AESIs
SAE Form	Hospitalisation or death	<ul style="list-style-type: none"> • Capillary blood sample Hb measurement • Other laboratory tests • Clinical management • Classification of SAE 	<ul style="list-style-type: none"> • Hb, other laboratory tests • Clinical management • SAE classification
Community Pharmacovigilance	Continuous	<ul style="list-style-type: none"> • Passive detection of SAEs and AESIs 	<ul style="list-style-type: none"> • All SAEs and AESIs
Qualitative	Continuous	<ul style="list-style-type: none"> • IDI, focus groups with patients, key stakeholders and community members of acceptability of revised case management strategy 	<ul style="list-style-type: none"> • Transcripts and summaries of interviews • Observations notes and memos

246

247

G6PD: Glucose-6-phosphate dehydrogenase; Hb: haemoglobin; MetHb: Methaemoglobin SAE: serious adverse event; AESI: adverse event of special interest; IDI: in-depth interview.

248

249

250

251 *Stage 2*

252 The Stage 2 implementation study will run for 12 months and will recruit all eligible patients with *P.*
253 *vivax* mono- or mixed species infection presenting to one of 10 study clinics across Indonesia and
254 PNG. Conditions during this stage are designed to emulate real-world practice as closely as possible.
255 Stage 2 will follow the same study procedures as Stage 1, except that clinic (rather than research)
256 staff will perform consent procedures and G6PD testing, and follow-up will be reduced to a single
257 clinical review (either in person or by phone) on day 3 (Supplementary Data 3; Level 1 Review Form).
258 The latter will be conducted by a Community-Based Health Worker (CbHW) or village midwife rather
259 than a research nurse. Patients with symptoms or signs of AESIs or SAEs will be referred to the clinic
260 for a Level 2 or Level 3 clinical review (Supplementary data 3; Level 2 and Level 3 Review Form). The
261 subsequent review and management of the patient will be the same as in Stage 1, with referral to
262 the site medical practitioner as necessary. In Stage 2, patients re-presenting with vivax malaria will
263 be eligible for repeat enrolment (Table 5).

264

265 **Table 5** Procedure and Clinical Data Collection in Stage 2.

	Day of Collection	Study Procedures	Data Collection
Enrolment and baseline	Day 0	<ul style="list-style-type: none">• Clinical review• Capillary blood for malaria diagnosis by microscopy or rapid diagnostic test (clinic procedure)• Written informed consent• If malaria positive, a 2nd capillary sample for G6PD and Hb measurement• Treatment prescribed• Education package• Supervision of first dose of DHP and PQ	<ul style="list-style-type: none">• Routine clinic data• Day 0 Hb and G6PD activity

		•	
Level 1 Review	Day 3	<ul style="list-style-type: none"> • Symptom questionnaire by CbHW 	<ul style="list-style-type: none"> • Patient follow-up • Symptoms and signs of patients referred to clinic • SAEs and AESIs
Level 2 Review	When referred from Level 1 review or patient presenting to health facility	<ul style="list-style-type: none"> • Capillary blood sample for Hb measurement • Signs and symptoms questionnaire by clinic nurse 	<ul style="list-style-type: none"> • Day 3 signs and symptoms • Day 3 Hb • SAEs and AESIs
Level 3 Review	When referred from Level 2	<ul style="list-style-type: none"> • Capillary blood sample Hb measurement • Signs and symptoms questionnaire by medical practitioner 	<ul style="list-style-type: none"> • Hb, Met Hb • Signs and symptoms • SAEs and AESIs
Community Pharmacovigilance	Continuous	<ul style="list-style-type: none"> • Passive detection of SAEs and AESIs 	<ul style="list-style-type: none"> • All SAEs and AESIs
Qualitative Interviews, focus group discussions (FGDs), Photovoice and observations	Continuous	<ul style="list-style-type: none"> • IDI, focus groups with key stakeholders and community members of acceptability of revised case management strategy • Photovoice (PNG only) with community members of revised case management strategy 	<ul style="list-style-type: none"> • Transcripts and summaries of interviews and FGDs • Observations notes and memos • Photos, summaries of transcripts from photovoice FGDs.
Health Economic Survey	Day 0 and Day 7 for household costs Continuous for provider costs	<ul style="list-style-type: none"> • Household cost survey per <i>P. vivax</i> episode at each clinic • Ingredients-based provider costs at selected clinics 	<ul style="list-style-type: none"> • Direct and indirect costs to patients and any caregivers • Provider costs for each component of the revised case management strategy
Post-implementation Survey	6 months into Stage 2	<ul style="list-style-type: none"> • Written informed consent • Capillary blood sample for malaria diagnosis, G6PD and Hb 	<ul style="list-style-type: none"> • Malaria diagnosis, Hb and G6PD activity

266 G6PD: Glucose-6-phosphate dehydrogenase; Hb: haemoglobin; MetHb: Methaemoglobin; SAE: serious adverse event; AESI:
267 adverse event of special interest; IDI: in-depth interview; CbHW: community-based health worker.

268

269

270

271 *Health Economics*

272 Detailed cost questionnaires will be completed by 30 consecutive patients (or their guardians)
273 presenting with *P. vivax* malaria at each clinic (total of 300 patients) to determine the direct and
274 indirect costs to households. In Indonesia, this will be completed during the pre-implementation
275 stage and the final 6 months of Stage 2. In PNG, only one data collection timepoint per clinic will be
276 completed. Data will also be collected on the costs of community engagement meetings, patient
277 education, clinical reviews, pharmacovigilance, staff training, serious adverse events (where relevant)
278 and malaria surveillance.

279

280 *Social Science*

281 During pre-implementation, purposive sampling of key stakeholders will be used to identify
282 participants for in-depth interviews to determine the acceptability and operational feasibility of
283 G6PD testing. Focus group discussions and in-depth interviews with malaria program officers at the
284 clinics, provincial and district health office representatives and health care providers will be held
285 during Stage 1 and Stage 2 to gather information on the practicality of the revised case management,
286 challenges for implementation, and inefficiencies. Community-based health workers will also be
287 involved in focus group discussions. In PNG, a subset of community members that test positive with
288 *P. vivax* will be invited to be involved photovoice, to critically reflect on the clinical reviews and PQ
289 adherence during day 3 and day 7 follow ups. Participant observations, informal conversations and
290 community engagement methods will be undertaken at the health clinics and certain sites in the
291 villages at several points during Stage 1 and Stage 2, across both PNG and Indonesia. The number of
292 participants involved in the social science research will vary by site, but the aim will be to reach a
293 broad spectrum of demographics, including participants of different ethnicity, sex and age (Table 6).

294

295 **Table 6** Qualitative research activities

Activity	Participants	Time	Location	Duration	Audio recording
In-depth interviews	Clinic staff, patients (or their guardians), local health authorities, community leaders	Scheduled with participants during Stage 1 and 2	Participant's office/ clinic/ house/ research office (as appropriate and agreed upon with the participant)	45-90 minutes	Recorded if participant consented
Focus group discussions	Clinic staff, community-based health workers involved in community-based clinical review	Scheduled with participants during Stage 1 and 2	Clinic/ Research office/ community centre (as appropriate and agreed upon with the participants)	45-90 minutes	Recorded with participants' consent
Observations and informal interviews	Clinic staff, patients, community members	During community engagement activities in pre-implementation stage (community members) and at different time points throughout Stage 1 and Stage 2 (all participants)	Clinic, public places where community activities take place (e.g. community centres, religious congregations)	The whole duration of activity being observed	No audio recording
Photovoice (PNG Only)	Community members	Photovoice will be used to critically reflect on the clinical reviews and PQ adherence during day 3 and day 7 follow ups and will be undertaken with patients that test positive for P. vivax malaria and are prescribed PQ.	Community center (as appropriate and agreed upon with the participants)	4–6-week process of photo taking and co-analysis with community members	Audio recording of FGDs during co-analysis

297

298 Study objectives and related endpoints

299 The overall objective of the SCOPE study is to determine the safety, feasibility and cost-effectiveness
 300 of high-dose primaquine after point of care G6PD testing. The study has additional subsidiary
 301 objectives with associated endpoints, subdivided by study stage and objective category addressing
 302 operational feasibility, cost-effectiveness, safety and pharmacovigilance (Table 7). The two primary
 303 endpoints in Stage 1 include the proportion of patients experiencing at least one SAE during
 304 treatment and the proportion of patients experiencing at least one AESI during treatment. In Stage 2
 305 the primary endpoint is the proportion of patients with *P. vivax* malaria who correctly receive all
 306 components of revised case management (including G6PD testing, treatment with PQ according to
 307 the revised case management protocol and G6PD activity, patient education, supervision of the first
 308 dose of PQ and community review on day 3).

309 **Table 7** Study objectives and endpoints

Stage 1 Objectives and related endpoints (n=800)	
Primary Objective	Primary Endpoints
To determine the safety of PQ in patients prescribed different treatment regimens	<ul style="list-style-type: none"> • Proportion of patients experiencing at least one SAE during treatment • Proportion of patients experiencing at least one AESI during treatment
Secondary Objectives	Secondary Endpoints
<ul style="list-style-type: none"> • Determine the risk of patients experiencing any AESI during treatment • Determine the risk of patients experiencing severe GI events during treatment • Determine the risk of patients experiencing severe haemolysis during treatment • Determine the risk of patients experiencing severe methaemoglobinaemia • Determine the tolerability of PQ in patients prescribed different treatment regimen • Determine primaquine dosing accuracy by G6PD activity category • Determine the proportion of patients receiving a clinical review on day 3 and day 7 of PQ treatment • Qualitative assessment of potential bottlenecks 	<ul style="list-style-type: none"> • The proportion of patients with any AESI during treatment • The proportion of patients with a gastrointestinal AESI during treatment. • The proportion of patients with an AESI related to haemolysis during treatment • The proportion of patients with an AESI related to methaemoglobinaemia • Proportion of patients permanently stopping PQ before end of treatment • The proportion of patients receiving correct treatment based on G6PD activity • Proportion of patients who were reviewed on day 3 and day 7 • Perception of and experience with new radical cure tools among health care providers and

to the revised case management (G6PD testing, high dose 7-day primaquine, and day 3 & day 7) to improve the implementation during Stage 2.	community members.
Stage 2 Objectives and related endpoints (n=11,410)	
Primary Objective	Primary Endpoint
To determine the operational feasibility of implementing revised case management for patients with <i>P. vivax</i> malaria	Proportion of patients with <i>P. vivax</i> malaria who correctly receive all components of revised case management (including G6PD testing, correct treatment of PQ according to revised case management and G6PD activity, patient education, supervision of the first dose and community review on day 3)
Operational Feasibility – Quantitative:	
Secondary Objectives	Secondary Endpoints
<ul style="list-style-type: none"> • Determine the proportion of health care practitioners who comply with the revised radical cure treatment algorithm • Determine the proportion of patients with vivax malaria receiving a SD Biosensor G6PD test • Determine primaquine dosing accuracy by G6PD activity category • Determine the proportion of vivax malaria patients who are ineligible for daily primaquine and are incorrectly given primaquine (including infants, pregnant females and G6PD deficient patients) • Determine the proportion of vivax malaria patients that are reviewed on day 3 • Determine the proportion of vivax malaria patients that adhere to their prescribed primaquine regimen 	<ul style="list-style-type: none"> • Proportion of health care practitioners who comply with the revised radical cure treatment algorithm • Proportion of patients with vivax malaria receiving a SD Biosensor G6PD test • Proportion of eligible vivax malaria patients receiving the correct dose of primaquine based on the result of the G6PD test • Proportion of vivax malaria patients who are ineligible for daily primaquine and are incorrectly given primaquine (including infants, pregnant females and G6PD deficient patients) • Proportion of vivax malaria patients that are reviewed on day 3 • Proportion of vivax malaria patients that adhere to their prescribed primaquine regimen
Operational Feasibility – Qualitative	
Secondary Objectives	Secondary Endpoints
<ul style="list-style-type: none"> • Understanding the acceptability and feasibility of the introduction and use of radical cure tools among health care providers. • Reviewing the barriers and enablers of uptake and implementation at sub-national levels. • Understanding the compliance with G6PD testing and perceptions of the drug regimens and serious adverse events among health care providers. • Understanding the knowledge, skills and training required for health care providers to administer the revised case management and patient-counseling. • Understanding the barriers and facilitators to 	<ul style="list-style-type: none"> • Factors influencing acceptability and feasibility of the new radical cure tools among health care providers are identified. • Barriers and enablers of uptake and implementation at the sub-national levels are identified • Factors influencing compliance with G6PD testing and perceptions of new drug regimens and serious adverse events among health care providers are identified • Required knowledge, skills, and training to administer the revised case management and patient-counseling identified • Factors influencing the barriers and facilitators to

<p>patient acceptance of G6PD testing and adherence to primaquine after the roll-out of the revised case management.</p> <ul style="list-style-type: none"> • Understanding the acceptability and feasibility of community-based clinical review at day 3 of primaquine treatment to detect and manage adverse effects. • Understanding the perceptions of new radical cure tools and serious adverse events at the community level • Determining the local acceptability of the revised case management algorithms among patients, their families and health care workers. 	<p>patient adherence to primaquine after the roll-out of the revised case management identified.</p> <ul style="list-style-type: none"> • Factors influencing the acceptability and feasibility of community-based clinical review at day 3 of primaquine treatment identified • Perceptions of the new radical cure tools and serious adverse events at the community level identified. • Local acceptability of the revised case management algorithms among patients, their families, and health care workers established.
<p>Cost-effectiveness:</p>	
<p>Secondary Objectives</p> <ul style="list-style-type: none"> • Determine if the burden of <i>P. vivax</i> malaria and asymptomatic parasitaemia decreases after the introduction of the revised case management • Determine the costs of the revised case management package from healthcare provider and societal perspectives • Determine the overall cost-effectiveness of the revised case management 	<p>Secondary Endpoints</p> <ul style="list-style-type: none"> • The monthly incidence of confirmed symptomatic <i>P. vivax</i> malaria episodes (mono infection or mixed) in the Pre-Implementation stage (minimum 3 months) versus Implementation Stage 2 (12 months) • Prevalence of <i>P. vivax</i> parasitaemia in patients presenting with fever in the Pre-Implementation Survey versus the Post-Implementation Survey during Stage 2 • Cumulative risk of representation to the same clinic with symptomatic <i>P. vivax</i> malaria within 6 months in the Pre- and Post-Implementation Stage • Cost per component of the revised case management package from a healthcare provider perspective, including health systems strengthening processes • Cost per episode of <i>P. vivax</i> malaria in the Pre-Implementation and Implementation Stages from the healthcare provider and societal perspectives in Indonesia. • Cost per episode of <i>P. vivax</i> malaria from the healthcare provider and societal perspectives in PNG. • Overall cost-effectiveness of changing policy if revised case management is effective as compared to usual care
<p>Pharmacovigilance:</p>	
<p>Secondary Objectives</p> <ul style="list-style-type: none"> • Determine the proportion of community-based health workers who correctly act on early signs of haemolytic anaemia and GI events 	<p>Secondary Endpoints</p> <ul style="list-style-type: none"> • Proportion of CbHWs who correctly act on early signs of haemolytic anaemia and GI events (i.e. refer patients for further medical review, instruct

<ul style="list-style-type: none"> Determine the number of patients identified through community surveillance system with serious adverse events 	<ul style="list-style-type: none"> patient to discontinue treatment) Number of patients with an SAE who are identified by community or clinic staff follow-up and referred to hospital for further management
Safety:	
Secondary objectives	Secondary endpoint
<ul style="list-style-type: none"> Determine the safety of PQ under real-world conditions Determine the risk of patients experiencing at least one AESI during treatment Determine the risk of patients experiencing severe haemolysis during treatment Determine the risk of patients experiencing severe GI event during treatment Determine the risk of patients experiencing severe methaemoglobinaemia Determine the difference in severe anaemia prevalence between the pre- and post-implementation of the revised case management 	<ul style="list-style-type: none"> The proportion of patients eligible to receive PQ who had a serious adverse event (SAE) during treatment The proportion of patients experiencing at least one AESI during treatment The proportion of patients with an AESI related to haemolysis during treatment The proportion of patients with a gastrointestinal AESI during treatment The proportion of patients with AESI related to methaemoglobinaemia Prevalence of severe anaemia in patients presenting with fever in the Pre-Implementation Survey versus the late Post-implementation Survey (derived from the quantitative surveys)

310 G6PD: Glucose-6-phosphate dehydrogenase; PQ: Primaquine; SAE: serious adverse event; AESI: adverse event of special
 311 interest; GI: gastrointestinal; CbHW: community-based health worker

312

313 Study participant selection and recruitment

314 Criteria for participation in the SCOPE study differ between the stages of the study (Table 2). To be
 315 included in the pre or post-implementation cross-sectional prevalence surveys, patients must have
 316 presented to a study clinic with fever or history of fever within the last 48 hours and must consent to
 317 the study procedures, including providing a finger-prick blood sample. For inclusion in Stage 1 or
 318 Stage 2, patients must be >6 months of age and >5kg in weight (Indonesia) and >1 year of age in PNG
 319 with microscopically or RDT-confirmed *P. vivax* mono- or mixed species infection. Patients will be
 320 excluded from the Stage 1 and Stage 2 studies (but not routine malariometric surveillance data
 321 collection) if they have a haemoglobin <8g/dL, are pregnant or breastfeeding an infant <6 months of
 322 age in Indonesia or <12 months of age in PNG, have had a previous adverse reaction to primaquine,
 323 have evidence of severe malaria or need hospital admission or referral. Participants in the various
 324 qualitative components of the study will be selected purposively to ensure adequate demographic

325 distribution and representation from key stakeholders (Table 8). Patients with vivax malaria who
 326 participate in the SCOPE study will receive a unique identification number along with a brief malaria-
 327 related medical summary. Patients will be asked to bring their unique number with them for any
 328 future appointments to enable linkage of repeated episodes.

329 **Table 8.** Participant recruitment and staff involved

Consent	Person recruiting	Consent Location	Method of recruitment
Stage 1	Research Staff	Clinic	All patients with suspected malaria presenting at the clinic will be screened. Eligible patients will be given the option to participate. During the consent process, the additional activities required for the research component will be discussed.
Stage 2	Clinic Staff guided by Research Staff		
Pre-implementation survey	Research Staff		200 patients with suspected malaria presenting at each clinic will be screened and if eligible they will be given the option to participate.
Post-implementation survey			
Qualitative and Health Economics			
- Economic surveys	Research Staff	Clinic	Consecutive patients (or their guardians) will be asked to participate in a short survey at the end of their visit until the required sample of 30 patients at each stage at each clinic is reached.
- In-depth Interviews		Community	Purposive sampling will be used to recruit Clinic Staff involved in G6PD testing, prescription of high dose PQ, and patient education.
			Purposive sampling will be used to recruit sub-national health authorities directly supervising malaria programs (e.g. Director of Public Health, Malaria Control Supervisors) and community leaders (e.g. village chiefs, religious leaders). Purposive sampling will be used to recruit community members with malaria (or parents of children with malaria) who attended study clinics. Participants will be identified during participant observations and subsequently contacted through community based health workers or Research Staff (or directly, if previous rapport has been established with the research team member) and asked to consent for interview.
- Focus group discussions			Community-based health workers involved in community-based clinical review will be invited to participate. Community members of similar age (≥ 18 years only), gender, and ethnicity will be approached through community-based health workers or community leaders to ask for initial consent.
- Participant		Clinic	Daily activities at the clinic will occur in the lab, outpatient desk and the pharmacy. These will be

observations			observed with permission from clinic manager. Informal conversations with Clinic Staff will be held during observation activities.
		Community	Research Staff will participate in public activities such as religious congregations, monthly child growth monitoring conducted by community health workers, home-based management of malaria programs etc. Informal conversations will be held with a spectrum of community members during observation activities.
- Photovoice (PNG Only)	Research staff	Community	Purposive sampling will be used to recruit community members with malaria who attended study clinics and participated in the initial interviews.

330 G6PD: Glucose-6-phosphate dehydrogenase; PQ: Primaquine.

331

332 Participant Consent

333 Individual written informed consent collected by trained researchers and clinic healthcare workers
 334 will be obtained from participants (or their guardians in the case of minors) in the pre-and post-
 335 implementation cross-sectional surveys, Stages 1 and 2, economic surveys, in-depth interviews, focus
 336 group discussions and photovoice. In Indonesia, minors over the age of 11 years will be asked to sign
 337 an assent form in addition to full written consent provided by their legal guardian. All patient
 338 information and the consent documents will be provided in the relevant local language. Provisions
 339 have been made for participants who are illiterate to have the consent documents read to them and
 340 their written consent recorded via a "mark" witnessed by a third party independent of the study
 341 team. Patients declining to participate in Stages 1 or 2 will receive malaria care as per national
 342 guidelines. Participants will be told that they can withdraw consent at any time without risk of
 343 prejudice, and only their data up to the time of withdrawal will be retained. Participants will remain
 344 in the study for the duration of their treatment, and their completion of the study will be facilitated
 345 by the community-based reviews. For qualitative observations of health workers, a waiver of consent
 346 was granted by all ethics committees, and health centres will be made aware that observations on
 347 staff will be carried out.

348

349 Patient and Public Involvement

350 Before the study commences, in-depth stakeholder engagement sessions will be held with clinic staff,
351 community leaders, religious and secular leaders, and the Ministries of Health. Engaged participants
352 will have the opportunity to provide feedback on the operating procedures and patient educational
353 materials and where possible, their feedback will be incorporated into the study. Community
354 awareness and engagement sessions in villages within the health facility catchment area will also be
355 conducted with the support of community leaders and clinic staff.

356 After the study is completed, there will be a process of community engagement with clinic staff,
357 community leaders and community members to describe the results of the study and to gather
358 feedback on possible refinement of future vivax malaria management and mechanisms for expansion
359 into routine practice. Findings will be discussed with representatives from the respective National
360 Malaria Control Programmes with respect to the viability of the intervention in terms of safety,
361 feasibility, and cost-effectiveness.

362

363 Power and Sample Size

364 In Stage 1, 4 clinics will enrol 800 patients (500 in Indonesia and 300 in Papua New Guinea).
365 Assuming 764 of these patients will have a G6PD activity >70% and be eligible for PQ7 and
366 considering that the proportion of patients receiving short-course primaquine who have to stop
367 therapy within 7 days is 5%, this sample size will produce a 95% confidence interval for the true
368 proportion needing to stop treatment with a margin of error +/- 1.55%.

369

370 In Stage 2, the implementation study will be conducted at ten health facilities across Indonesia and
371 Papua New Guinea. Based on recruitment during Stage 1 and prior surveillance, we estimate a total
372 of 11,410 patients with vivax malaria will be eligible and recruited into Stage 2 in Indonesia and
373 Papua New Guinea. Across the 10 clinics participating in Stage 2, a mean of 136 patients with vivax

374 malaria are expected to be seen at each clinic per month, 60% of which (n=82) are predicted to be
375 relapses and therefore preventable with improved primaquine therapy. Assuming the
376 implementation package in Stage 2 will reduce the individual risk of relapse by 30%, the monthly
377 incidence of vivax malaria is expected to fall by 17 cases (12.6%) per month. With a two-sided alpha
378 of 0.05 and a predicted standard deviation of the mean variation in monthly numbers of vivax
379 malaria cases at each clinic of 15, our sample size would achieve 89% power to detect this difference
380 in incidence.

381

382 The risk of recurrence will also be assessed at an individual level using comparisons with patients
383 recruited during the pre-implementation phase. Based on a presumptive sample size of 11,410
384 patients matched 1:1 with 11,410 patients with vivax malaria in the pre-implementation phase, our
385 sample size would have 100% power to detect a 30% reduction in individual risk of recurrence at 6
386 months and 92% power to detect a 10% reduction, assuming 10% loss to follow-up in each group
387 and a baseline risk of recurrence at 6 months of 20%.

388 If 70% of patients recruited into Stage 2 receive all components of the implementation package
389 correctly, a sample size of 11,410 will give a 95% confidence interval for the true proportion of +/-
390 0.84%. If 1% of patients are predicted to have a treatment-limiting haemolytic event, this sample
391 size will produce an estimate with a 95% confidence interval of +/-0.18%.

392

393 Analysis

394 Quantitative analyses will be done according to an *a priori* statistical analysis plan (Supplementary
395 Data 5). Briefly, numbers (with denominators) and proportions receiving the components of the
396 intervention package and experiencing AESIs, or SAEs will be presented in graphical and tabular
397 format with associated 95% confidence intervals. The change in incidence of vivax malaria between
398 the pre-implementation Stage and Stage 2 will be shown graphically and the statistical significance
399 of observed changes will be assessed by fitting a segmented regression model accounting for

400 autocorrelation with adjustment for time-varying cofactors. For before versus after comparisons of
401 count data, such as number of vivax malaria cases per month, incidence rate ratios will be calculated
402 and negative binomial regression models fitted. Individual-level risk of representation with vivax
403 malaria will be calculated using survival techniques including Kaplan-Meier curves and Cox
404 proportional hazards regression.

405

406 The costs to patients and their families of *P. vivax* infection and the total healthcare provider costs
407 (including costs of community engagement meetings, the patient education package, clinical
408 reviews, pharmacovigilance, staff training, severe adverse events (where relevant), and malaria
409 surveillance), will be used in combination with before-and-after case numbers to determine the
410 overall cost-effectiveness of the package of revised case management (cost per infection or
411 disability-adjust life-year averted). Pending discussions with decision makers, this may include a
412 budget impact analysis and/or a distributional cost-effectiveness analysis.

413

414 Qualitative data will be set-up in a preliminary coding tree in NVivo based on operational
415 conceptualisation of relevant outcomes of the study, i.e., feasibility, acceptability and risk appraisal.
416 All written data will subsequently be entered and coded into the same NVivo project. Deductive
417 coding based on the preliminary coding tree and inductive coding to yield new findings will be done.
418 For Photovoice, analysis involves the collective interpretation of images by the community members
419 as a way of co-creating knowledge and co-constructing meaning. To facilitate the group discussions
420 of the photographs, the SHOWED guide is used with the following questions: What do we see here?
421 What is really happening here? How does this relate to our lives? Why does this concern, situation
422 or strength exist? How can we become empowered through our new understanding? What can we
423 do?

424

425 ETHICS AND DISSEMINATION

426 *Ethics approval*

427 This study protocol (Master Protocol Version 4.0, 28 April 2023) was approved by the World Health
428 Organization Ethics Committee (Indonesia: ERC 0003810, PNG ERC 0003892); Menzies School of
429 Health Research (HREC: 2023-4524), Alfred Health (Burnet Institute, Project No: 18/23), University of
430 Gadjah Mada (KE/FK/0079/EC/2023), University of Indonesia (KET
431 347/UN2.F1/ETIK/PPM.00.02/2023), University of Sumatra Utara (80/KEPK/USU/2023), Institute of
432 Tropical Medicine (1655/23), PNG Institute of Medical Research (PNGIMR) (IRB: 22.02), and the PNG
433 National Department of Health Medical Research Advisory Committee (MRAC: 22.66). The study was
434 registered on clinicaltrials.gov for Indonesia: NCT05879224 and PNG: NCT05874271. Changes to
435 protocols will be communicated to all involved ethics boards and relevant institutions and updated in
436 the clinical trials registration. Stage 1 of the study began in October 2023 and was completed in
437 September 2024.

438

439 *Participant Safety*

440 Although pre-treatment G6PD testing will reduce the risk of severe drug-induced haemolysis, the risk
441 cannot be eliminated completely. Severe haemolysis may still occur from *P. vivax* parasitaemia alone,
442 misdiagnosis of G6PD status (due to an erroneous SD Biosensor result or human error by
443 misinterpretation or incorrect prescription of PQ) or another concomitant, undiagnosed
444 haemoglobin or red cell pathology such as the thalassaemia's. Staff will receive refresher training
445 sessions on the correct use of the SD Biosensor device and regular quality control will be undertaken
446 to reduce measurement error. The day 3 (and in the case of Stage 1, the day 7) clinical review has
447 been timed to maximise the likelihood of early detection of impending haemolysis or other severe
448 adverse effects of primaquine. Conservative and standardised clinical escalation pathways are
449 designed to adjust management strategies to mitigate the risk of adverse outcomes. (Figure 4).

450 **Figure 4.** Patient Review (Level 1, 2 and 3) and Adverse Event Collection Process.

451 Footnote: Study MD: Study medical doctor; PI: principal investigator; GMM: global medical monitor; MMV CMO:
452 Medicines for Malaria Venture Chief Medical Officer.

453

454 *Adverse Event Detection and Categorisation*

455 The severity of adverse events will be graded according to the NCI Common Terminology Criteria for
456 Adverse Events (CTCAE vs 5.0) (33). In addition, the Hillmen urine colour chart will be used during
457 patient clinical reviews (34). Adverse Events of Special Interest (AESI) include haemolysis,
458 gastrointestinal events and methaemoglobinaemia. Criteria for a haemolytic AESI include one or
459 more of the following with onset after commencing PQ:

- 460 i. Grade 3 or 4: fatigue, breathlessness or dizziness
- 461 ii. Severe pallor or jaundice
- 462 iii. Dark urine (Hillmen score >7)
- 463 iv. Fall in haemoglobin from baseline >3g/dL
- 464 v. Fall in haemoglobin to <7g/dL

465 Gastrointestinal AESI criteria include Grade 3 or 4 abdominal pain, nausea, anorexia or vomiting, and
466 methaemoglobinaemia AESI criteria include: methaemoglobin >10%, with Grade 3 or 4
467 breathlessness or dizziness (Supplementary Data 4).

468 Serious Adverse Events (SAE) will be defined as an untoward medical occurrence irrespective of
469 cause that occurs after commencement of PQ that: results in death, is life threatening, requires
470 inpatient hospitalisation or prolongs existing hospitalisation, results in persistent or significant
471 disability/incapacity, is a congenital anomaly/birth defect or requires medical intervention to prevent
472 permanent impairment or damage.

473

474 Follow-up and Review of Adverse Events

475 Clinical referral pathways will be established for patients requiring advanced management of
476 haemolysis or other adverse reactions. Community-based health care workers will actively engage
477 communities during Stage 2 follow-up visits to identify individuals who died or required hospital
478 admission, blood transfusion or dialysis after day 3. Prior to commencing the study,
479 pharmacovigilance awareness will be raised in the community and at the emergency departments at
480 local referral hospitals.

481 Immediately upon detection of an AESI or SAE, a cascade of adverse event reporting will be initiated
482 including submission of the Level 3 safety review and SAE form (if applicable) to the Study Doctor,
483 Global Medical Monitor (GMM), Principal Investigators, Study Sponsor and Chief Medical Officer
484 from Medicines for Malaria Venture. Where possible follow-up details of each event will be provided
485 to the GMM. Community-based health workers, research nurses and site medical practitioners will
486 take all appropriate steps to protect the safety of participants and will ensure follow-up of the
487 evolution of each adverse event until resolution or permanent stabilisation. The GMM will gather all
488 safety data and report to the Safety Review Team (SRT).

489 Data management

490 In Indonesia, hard copy clinic register, and case report forms will be stored in locked filing cabinets at
491 the clinics. Data from these forms will be transcribed into an electronic format using REDCap
492 (v14.6.11) data capture software. In PNG, all data will be collected directly into REDCap (v14.6.9)
493 software (35, 36). Automatic checks of data validity will be built into the data entry forms. Verbal
494 data from qualitative surveys will be recorded in MP3 or WAV format and subsequently transcribed
495 into written form using standard word processing software. Patient identifiers will be stripped from
496 datasets once data cleaning and preparation is complete. Deidentified research data will be stored
497 for the long-term in the original electronic format, in a unified large database that contains all
498 research data other than participant identifiable data.

499

500 **Data monitoring**

501 *Study coordination*

502 The study will be coordinated by two sponsors 1) Menzies School of Health Research, Darwin,
503 Australia (with study sites in Papua; Sumatera Utara; and Lampung, Indonesia, managed by YPKMP/
504 Universitas Gadjah Mada; Universitas Sumatra Utara; and University of Indonesia, respectively), and
505 2) Burnet Institute, Melbourne, Australia (with study sites in Baro, Mugil, Napapar and Wirui,
506 managed by the Papua New Guinea Institute of Medical Research). The sponsors will provide study
507 oversight via the principal investigators. Additionally, Medicines for Malaria Venture (MMV),
508 Geneva, will provide overall study oversight to the study sponsors. An insurance policy from each
509 Sponsor, will cover any potential medical costs if a patient becomes sick or injured because of the
510 study. The investigators and sponsors will have access to the final dataset.

511

512 *Safety Review Team (SRT) and Safety Monitoring Committee (SMC)*

513 The SRT and SMC will be established to monitor safety and conduct of the study. The SRT will be
514 managed by the GMM, and include members from the global study team, with an independent
515 chair. The SMC will only include independent experts, and take place during Stage 1 only. The SRT
516 will meet after every 100 patients to monitor and review individual participant safety data, or at
517 an ad-hoc basis in the case of any safety events during Stage 1 (Figure 4). At each meeting, the
518 SRT will vote on whether the study should be continued, modified or stopped. Interim analyses
519 will be performed after 400 patients and after completion of Stage 1 (800 patients). The SRT will
520 review the data package at these time points and forward a proposal to the SMC regarding the
521 appropriateness of study continuation. The SRT will approve the progress to Stage 2 based on the
522 SMC recommendations and endorsement from National Departments of Health in each country.
523 The SRT will meet quarterly during Stage 2.

524

525 *Monitoring and Auditing*

526 A study monitoring plan with detailed monitoring templates has been prepared separately for
527 Indonesia and PNG. Each study site will have at least three monitoring visits throughout the study
528 period. The frequency may be increased based on the monitor's recommendations at each site.
529 Auditing will take place as per either the sponsor, MMV or the national health authority's request.

530 *Dissemination*

531 Dissemination plans include presentations at scientific conferences, peer-reviewed publications, and
532 reporting at the National Ministries of Health in both countries as well as provincial and district
533 health authorities in study locations.

534

535 **DISCUSSION**

536 Progress towards global elimination of *P. vivax* malaria has been slow, largely because of healthcare
537 providers' inability to prevent relapses safely and effectively. Recommended primaquine regimens
538 are prolonged and current doses are insufficient in many tropical areas. The risk of precipitating
539 drug-induced haemolysis in patients with G6PD deficiency limits the use of this critically important
540 drug in the many vivax-endemic areas where G6PD testing is unavailable. Short, high-dose
541 primaquine regimens have potential to improve patient adherence and thus treatment effectiveness
542 and rapid and reliable pre-treatment G6PD testing can facilitate individualised treatment for patients
543 and reduce the risk of adverse events. Shortened courses of primaquine at a total dose of 7mg/kg
544 are known to be efficacious for preventing relapse under trial conditions (23, 37) but the safety and
545 effectiveness in real-world use is unknown.

546 The SCOPE implementation study is designed to provide robust data on the feasibility, safety, costs,
547 and cost-effectiveness of having the typical primaquine treatment duration for patients with vivax

548 malaria reduced to 7-days, by introducing pre-treatment point of care G6PD activity assessment and
549 then providing double the usual primaquine total dose (7mg/kg), basic community
550 pharmacovigilance and enhanced patient education. Following the Stage 1 phase, study conditions
551 will emulate real-world practice as closely as possible.

552 This study has several important strengths. It will enrol a large number of patients with vivax malaria
553 and provide precise estimates of the frequency of key safety outcomes. Patients will be enrolled at
554 10 sites, encompassing widely disparate *P. vivax* endemicities ensuring generalisability of the results
555 to many endemic areas. The intensive first phase with rigorous community-based pharmacovigilance
556 ensures confidence in the safety of the interventions prior to large-scale roll-out in Stage 2 while
557 longstanding malariometric surveillance data collection at the study clinics will improve the
558 robustness of before-versus-after comparisons of vivax malaria incidence.

559 The study has several limitations. Non-study malaria control activities will continue throughout the
560 study period and will confound analyses of temporal trends. Collection of informed consent for study
561 participation will impact clinic workflow and create a deviation from a true, real-world patient
562 experience. Patient migration, absence of a robust national identification system, and diverse
563 treatment seeking behaviours may all result in incomplete detection of vivax malaria recurrence
564 resulting in an attrition bias affecting analyses of individual risk of recurrence.

565 The SCOPE study is endorsed by the Indonesian and PNG Ministries of Health and aligns with
566 national malaria control priorities. Evidence provided by this study is expected to guide national vivax
567 malaria management strategies in both countries and aim to contribute to reducing the burden of
568 vivax malaria.

569

570 LIST OF ABBREVIATIONS

571 ACT Artemisinin-based Combination Therapy

572	ADL	Activity of Daily Living
573	AE	Adverse Event
574	AESI	Adverse Event of Special Interest
575	CbHW	Community-based Health Worker
576	CQI	Continuous Quality Improvement
577	FGD	Focus Group Discussion
578	G6PD	Glucose-6-Phosphate Dehydrogenase
579	G6PDd	G6PD deficiency
580	GST	Global Study Team
581	HCP	Healthcare Provider
582	MoH	Ministry of Health
583	NDA	National Drug Authority
584	NDoH	National Department of Health
585	NMCP	National Malaria Control Program
586	PCR	Polymerase Chain Reaction
587	PNG	Papua New Guinea
588	PQ	Primaquine
589	PQ7	Primaquine 1.0 mg/kg/day for 7 days
590	PQ14	Primaquine 0.5 mg/kg/day for 14 days
591	PQ8W	Primaquine 0.75mg/kg/week for 8 weeks

592 RDT Rapid Diagnostic Test

593 SAE Serious Adverse Event

594 SCOPE Short COurse PrimaquinE for the radical cure of P. vivax

595 SMC Safety Monitoring Committee

596 SRT Safety Review Team

597 YPKMP Yayasan Pengembangan Kesehatan dan Masyarakat Papua (Papua Health and
598 Community Development Foundation)

599

600 **DECLARATIONS**

601 **Consent for publication:** All authors consent to publication

602 **Availability of data and materials:** The datasets that will be generated during the current study will
603 be made available from the corresponding authors on reasonable request.

604 **Competing interests:** The authors have no competing interests to declare

605 **Funding:** This study is funded by UNITAID. In Papua New Guinea this funding is funded through
606 PNGIMR, Burnet Institute in Melbourne, Victoria, Australia. In Indonesia this study is funded through
607 Yayasan Pengembangan Kesehatan dan Masyarakat Papua, and Menzies School of Health Research in
608 Darwin Australia.

609 **Patient and public involvement:** Patients and/or the public were involved consulted the design, or
610 conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for
611 further details.

612

613 **Provenance and peer review:** Not commissioned; externally peer reviewed

614 **Acknowledgements:**

615 We thank Emilie Alirol for assistance developing the design of the study and Piero Olliaro and

616 Arantxa Roca-Feltrer for reviewing advice on the study design and review of the protocol.

617

618 **Author contributions**

619 ML, JRP, AP, IS, RNP, LJR, ND, SD conceived the study and led the protocol development; ER, VSS, EN,

620 LF, MM, AR, RF, KM, PD, BL, PA, AD, GL, MT, AS, RN, SP, HH and EJ contributed to protocol

621 development. ML, JRP, AP, IS, RNP, LJR, ND, SD, JA, LF, FA, SA, AS, RN, MM, MOK, VSS, ER, GL, KM, PD,

622 TD, HH, HD, TW contributed to study materials development. JAS, ND and RNP developed the

623 statistical analysis plan and GL the data management plan. All authors read and approved the final

624 protocol manuscript.

625

626 References

- 627 1. Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in the Era of the
628 Shrinking P. falciparum Map. Trends Parasitol. 2020;36(6):560-70.
- 629 2. Commons RJ, Simpson JA, Watson J, White NJ, Price RN. Estimating the Proportion of
630 Plasmodium vivax Recurrences Caused by Relapse: A Systematic Review and Meta-Analysis. Am J
631 Trop Med Hyg. 2020;103(3):1094-9.
- 632 3. World Health Organisation. World Malaria Report 2023. 2023.
- 633 4. Rueangweerayut R, Bancone G, Harrell EJ, Beelen AP, Kongpatanakul S, Mohrle JJ, et al.
634 Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate
635 Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers. Am J
636 Trop Med Hyg. 2017;97(3):702-11.
- 637 5. Thriemer K, Ley B, von Seidlein L. Towards the elimination of Plasmodium vivax malaria:
638 Implementing the radical cure. PLoS Med. 2021;18(4):e1003494.
- 639 6. TGA. Australian Public Assessment Report: Tafenoquine succinate 2019 [Available from:
640 <https://www.tga.gov.au/resources/auspar/auspar-tafenoquine-succinate-0>.
- 641 7. FDA. Krintafel (Tafenoquine) 2018 [Available from:
642 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210795s000lbl.pdf.
- 643 8. FDA. Arakoda (Tafenoquine) Tablets 2018 [Available from:
644 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210607lbl.pdf.
- 645 9. Recht J, Ashley EA, White NJ. Use of primaquine and glucose-6-phosphate dehydrogenase
646 deficiency testing: Divergent policies and practices in malaria endemic countries. PLoS Negl Trop Dis.
647 2018;12(4):e0006230.
- 648 10. Mehdipour P, Rajasekhar M, Dini S, Zaloumis S, Abreha T, Adam I, et al. Effect of adherence
649 to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance
650 Network systematic review and individual patient data meta-analysis. Malar J. 2023;22(1):306.
- 651 11. Thriemer K, Ley B, Bobogare A, Dysoley L, Alam MS, Pasaribu AP, et al. Challenges for
652 achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN
653 Vivax Working Group. Malar J. 2017;16(1):141.
- 654 12. World Health Organisation. WHO Guidelines for Malaria. Geneva: WHO; 2023.
- 655 13. Devine A, Battle KE, Meagher N, Howes RE, Dini S, Gething PW, et al. Global economic costs
656 due to vivax malaria and the potential impact of its radical cure: A modelling study. PLoS Med.
657 2021;18(6):e1003614.
- 658 14. Paediatric Society of Papua New Guinea. Standard Treatment for Common Illnesses of
659 Children in Papua New Guinea. 2016.
- 660 15. Ministry of Health Republic of Indonesia. Pocket book on Malaria Case Management. 2023.
- 661 16. Rahmalia A, Poespoprodjo JR, Landuwulang CUR, Ronse M, Kenangalem E, Burdam FH, et al.
662 Adherence to 14-day radical cure for Plasmodium vivax malaria in Papua, Indonesia: a mixed-
663 methods study. Malar J. 2023;22(1):162.
- 664 17. Douglas NM, Poespoprodjo JR, Patriani D, Malloy MJ, Kenangalem E, Sugiarto P, et al.
665 Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern
666 Papua: A hospital-based cohort study. PLoS Med. 2017;14(8):e1002379.
- 667 18. Poespoprodjo JR, Burdam FH, Candrawati F, Ley B, Meagher N, Kenangalem E, et al.
668 Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax
669 malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial. Lancet
670 Infect Dis. 2021.
- 671 19. Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, et al. Comparison of
672 artemether-lumefantrine and chloroquine with and without primaquine for the treatment of
673 Plasmodium vivax infection in Ethiopia: A randomized controlled trial. PLoS Med.
674 2017;14(5):e1002299.

- 675 20. Baird JK, Hoffman SL. Primaquine Therapy for Malaria. *Clinical Infectious Diseases*.
676 2004;39(9):1336-45.
- 677 21. Commons RJ, Rajasekhar M, Edler P, Abreha T, Awab GR, Baird JK, et al. Effect of primaquine
678 dose on the risk of recurrence in patients with uncomplicated *Plasmodium vivax*: a systematic review
679 and individual patient data meta-analysis. *Lancet Infect Dis*. 2023.
- 680 22. Chu CS, Phyo AP, Turner C, Win HH, Poe NP, Yotyingaphiram W, et al. Chloroquine Versus
681 Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14
682 Days in *Plasmodium vivax* Malaria. *Clin Infect Dis*. 2019;68(8):1311-9.
- 683 23. Taylor WRJ, Thriemer K, von Seidlein L, Yuentrakul P, Assawariyathipat T, Assefa A, et al.
684 Short-course primaquine for the radical cure of *Plasmodium vivax* malaria: a multicentre,
685 randomised, placebo-controlled non-inferiority trial. *Lancet*. 2019;394(10202):929-38.
- 686 24. Luzzatto L. Glucose 6-phosphate dehydrogenase deficiency: from genotype to phenotype.
687 *Haematologica*. 2006;91(10):1303-6.
- 688 25. Rajasekhar M, Simpson JA, Ley B, Edler P, Chu CS, Abreha T, et al. Primaquine dose and the
689 risk of haemolysis in patients with uncomplicated *Plasmodium vivax* malaria: a systematic review and
690 individual patient data meta-analysis. *Lancet Infect Dis*. 2023.
- 691 26. Chu CS, Bancone G, Moore KA, Win HH, Thitipanawan N, Po C, et al. Haemolysis in G6PD
692 Heterozygous Females Treated with Primaquine for *Plasmodium vivax* Malaria: A Nested Cohort in a
693 Trial of Radical Curative Regimens. *PLoS Med*. 2017;14(2):e1002224.
- 694 27. Yilma D, Groves ES, Brito-Sousa JD, Monteiro WM, Chu C, Thriemer K, et al. Severe Hemolysis
695 during Primaquine Radical Cure of *Plasmodium vivax* Malaria: Two Systematic Reviews and Individual
696 Patient Data Descriptive Analyses. *Am J Trop Med Hyg*. 2023;109(4):761-9.
- 697 28. Ley B, Winasti Satyagraha A, Rahmat H, von Fricken ME, Douglas NM, Pfeffer DA, et al.
698 Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-
699 phosphate dehydrogenase deficiency: A systematic review and meta-analysis. *PLoS Med*.
700 2019;16(12):e1002992.
- 701 29. Pal S, Bansil P, Bancone G, Hrutkay S, Kahn M, Gornsawun G, et al. Evaluation of a Novel
702 Quantitative Test for Glucose-6-Phosphate Dehydrogenase Deficiency: Bringing Quantitative Testing
703 for Glucose-6-Phosphate Dehydrogenase Deficiency Closer to the Patient. *Am J Trop Med Hyg*.
704 2019;100(1):213-21.
- 705 30. Alam MS, Kibria MG, Jahan N, Thriemer K, Hossain MS, Douglas NM, et al. Field evaluation of
706 quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity. *PLoS*
707 *One*. 2018;13(11):e0206331.
- 708 31. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010
709 statement: extension to randomised pilot and feasibility trials. *Pilot and Feasibility Studies*.
710 2016;2(1).
- 711 32. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. *Annals of Internal*
712 *Medicine*. 2013;158(3):200-7.
- 713 33. Institute NC. Common Terminology Criteria for Adverse Events (CTCAE) 2020 [Available from:
714 https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm].
- 715 34. Hillmen P, Hall C, Marsh JCW, Elebute M, Bombara MP, Petro BE, et al. Effect of Eculizumab
716 on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria.
717 *New England Journal of Medicine*. 2004;350(6):552-9.
- 718 35. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
719 capture (REDCap)--a metadata-driven methodology and workflow process for providing translational
720 research informatics support. *J Biomed Inform*. 2009;42(2):377-81.
- 721 36. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium:
722 Building an international community of software platform partners. *J Biomed Inform*.
723 2019;95:103208.
- 724 37. Thriemer K, Degaga TS, Christian M, Alam MS, Rajasekhar M, Ley B, et al. Primaquine radical
725 cure in patients with *Plasmodium falciparum* malaria in areas co-endemic for *P falciparum* and

726 Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial. The
727 Lancet. 2023.
728

		UNITAID Funding		
	DFAT Funded			
	>6 months	3 months	6 months	12 months
			★ ★	
4 sites	Baseline Data	Pre-Implementation Stage	Stage 1 Safety & Feasibility	Stage 2 Implementation
6 sites	Baseline Data	Pre-Implementation Stage		Stage 2 Implementation


- ★ SMC review
- ☆ NDoH and NDA review


Enhanced continuous malarionetric health facility surveillance and pharmacovigilance

Qualitative assessment and quantitative surveys of acceptability, operational feasibility, performance, costs and passive *P. vivax* slide or mRDT positivity

Coordinated roll-out of revised case management

Qualitative assessment and quantitative surveys of acceptability, operational feasibility, performance, costs and passive *P. vivax* slide or mRDT positivity





Tanjung Leidong

4 clinics in Timika,
Papua

Hanura

Baro

Wirui

Mugil

Napapar

Research activities are marked blue

	Pre-implementation Stage	Stage 1				Stage 2		
	Day 0	Day 0	Day 3	Day 7	Unplanned Visit	Day 0	Day 3	Unplanned Visit
Location	Clinic	Clinic	Community or clinic by a nurse	Community or clinic by a nurse	Clinic	Clinic	Community by a CHW ¹	Clinic
Routine review and diagnosis	X	X				X		
Consent	X	X				X ²		
Capillary blood sample								
Hb	X	X	X	X	+/- X	X		+/- X
G6PD	X	X				X		
Microscopy	X				+/- X	X ³		+/- X
Treatment/Prescription	If applicable	X				X		
Education		X				X		
Supervision of first dose		X				X		
Drug supply	If applicable	X				X		
Adverse event data collection		X	X	X	X	X	X	X
Community pharmacovigilance ⁴		X	X	X	X	X	X	X

